Josep Bassaganya-Riera's guest appearances

Josep Bassaganya-Riera

Finding Genius Podcast

FutureTech Podcast

Laura Potterat

Marc Guell

Paul Turner

Jan Vijg

Eleftherios Mylonakis

Cory Kidd

Charles C.J

Helius Medical Technologies

Patrick McKeown

Michael G. Surette

Katelyn Parsons

John Tucker

Jake Kushner

Erik Gunther

Kim Kush

OwlTail

In this podcast, Josep Bassaganya-Riera, DVM, PhD, Chairman, CEO, and Founder of Landos Biopharma, an emerging biotech company, discusses their important work in the development of new therapeutics to combat autoimmune disease. Dr. Bassaganya-Riera has been part of major research funded by prestigious grants from institutions, such as the National Institutes of Health and the United States Department of Agriculture (USDA). Dr. Bassaganya-Riera is Principal Investigator and Director for the Modeling Immunity to Enteric Pathogens (MIEP) project that studies the immunoregulatory mechanisms underlying infections with select gut pathogens through the use and application of mathematical systems to mucosal immunology. Dr. Bassaganya-Riera talks about Landos Biopharma, the emerging biotech company that is creating a stir in the autoimmune disease research and therapeutic development field. Dr. Bassaganya-Riera explains some of the needs that are not currently being met by Crohn's disease treatment, and he talks about colitis—a chronic digestive disease identified by inflammation, often severe, of the colon’s innermost lining. Dr. Bassaganya-Riera talks about Landos Biopharma’s completion of phase one clinical trials. And the research doctor provides information on various other diseases of the gastrointestinal tract. He explains their leading clinical asset—BT-11—which is a new, oral, locally-acting molecule that specifically targets the Lanthionine Synthetase C-Like 2 (LANCL2) pathway in the GI tract for the treatment of inflammatory bowel disease. Dr. Bassaganya-Riera has published over 100 scientific papers, secured 9 patents, and he received the 2018 Research Excellence Award from the Biocomplexity Institute of Virginia Tech.

In this podcast, Josep Bassaganya-Riera, DVM, PhD, Chairman, CEO, and Founder of Landos Biopharma, an emerging biotech company, discusses their important work in the development of new therapeutics to combat autoimmune disease. Dr. Bassaganya-Riera has been part of major research funded by prestigious grants from institutions, such as the National Institutes of Health and the United States Department of Agriculture (USDA). Dr. Bassaganya-Riera is Principal Investigator and Director for the Modeling Immunity to Enteric Pathogens (MIEP) project that studies the immunoregulatory mechanisms underlying infections with select gut pathogens through the use and application of mathematical systems to mucosal immunology. Dr. Bassaganya-Riera talks about Landos Biopharma, the emerging biotech company that is creating a stir in the autoimmune disease research and therapeutic development field. Dr. Bassaganya-Riera explains some of the needs that are not currently being met by Crohn's disease treatment, and he talks about colitis—a chronic digestive disease identified by inflammation, often severe, of the colon’s innermost lining. Dr. Bassaganya-Riera talks about Landos Biopharma’s completion of phase one clinical trials. And the research doctor provides information on various other diseases of the gastrointestinal tract. He explains their leading clinical asset—BT-11—which is a new, oral, locally-acting molecule that specifically targets the Lanthionine Synthetase C-Like 2 (LANCL2) pathway in the GI tract for the treatment of inflammatory bowel disease. Dr. Bassaganya-Riera has published over 100 scientific papers, secured 9 patents, and he received the 2018 Research Excellence Award from the Biocomplexity Institute of Virginia Tech.

An Autoimmune Disease Conversation – Josep Bassaganya-Riera, DVM, PhD, Landos Biopharma – New Therapeutics for Autoimmune Disease Treatment

Josep Bassaganya-Riera, DVM, PhD, founder, Chairman and CEO of Landos Biopharma, delivers a fact-filled overview of his company’s work, developing safer therapeutics for autoimmune disease. Dr. Bassaganya-Riera has received numerous research grants from a wide variety of science and health institutions, including the National Institutes of Health, the United States Department of Agriculture (USDA), as well as many industrial corporations. Dr. Bassaganya-Riera holds the title of Principal Investigator and Director for the Modeling Immunity to Enteric Pathogens (MIEP) project, which investigates the various immunoregulatory mechanisms underlying infections with certain gut pathogens by introducing mathematical systems to current mucosal immunology. Dr. Bassaganya-Riera discusses his work with Landos Biopharma, an emerging biotech company that is already an integral player in the development of groundbreaking oral treatments for patients who suffer from autoimmune diseases. He discusses the unmet needs in Crohn's disease treatment in detail, as well as colitis—a chronic digestive disease recognized by inflammation of the colon’s inner lining. Dr. Bassaganya-Riera discusses their successful completion of phase one clinical trials, and he talks about his enthusiasm for further advancement of their therapeutics. The research doctor discusses other diseases of the gastrointestinal tract. He outlines their progress thus far and explains their lead clinical asset, BT-11, which is a unique, oral, locally-acting tiny molecule that targets the Lanthionine Synthetase C-Like 2 (LANCL2) pathway in the gastrointestinal tract for the treatment of IBD (inflammatory bowel disease). Dr. Bassaganya-Riera has a prolific track record of publishing and securing his important work and has published over 100 scientific papers, and secured 9 patents. He was awarded the 2018 Research Excellence Award from the prestigious Biocomplexity Institute of Virginia Tech.

Josep Bassaganya-Riera, DVM, PhD, founder, Chairman and CEO of Landos Biopharma, delivers a fact-filled overview of his company’s work, developing safer therapeutics for autoimmune disease. Dr. Bassaganya-Riera has received numerous research grants from a wide variety of science and health institutions, including the National Institutes of Health, the United States Department of Agriculture (USDA), as well as many industrial corporations. Dr. Bassaganya-Riera holds the title of Principal Investigator and Director for the Modeling Immunity to Enteric Pathogens (MIEP) project, which investigates the various immunoregulatory mechanisms underlying infections with certain gut pathogens by introducing mathematical systems to current mucosal immunology. Dr. Bassaganya-Riera discusses his work with Landos Biopharma, an emerging biotech company that is already an integral player in the development of groundbreaking oral treatments for patients who suffer from autoimmune diseases. He discusses the unmet needs in Crohn's disease treatment in detail, as well as colitis—a chronic digestive disease recognized by inflammation of the colon’s inner lining. Dr. Bassaganya-Riera discusses their successful completion of phase one clinical trials, and he talks about his enthusiasm for further advancement of their therapeutics. The research doctor discusses other diseases of the gastrointestinal tract. He outlines their progress thus far and explains their lead clinical asset, BT-11, which is a unique, oral, locally-acting tiny molecule that targets the Lanthionine Synthetase C-Like 2 (LANCL2) pathway in the gastrointestinal tract for the treatment of IBD (inflammatory bowel disease). Dr. Bassaganya-Riera has a prolific track record of publishing and securing his important work and has published over 100 scientific papers, and secured 9 patents. He was awarded the 2018 Research Excellence Award from the prestigious Biocomplexity Institute of Virginia Tech.

In Tune to Autoimmune – Josep Bassaganya-Riera, DVM, PhD, Founder, Chairman and CEO of Landos Biopharma – Safer Therapeutics for Autoimmune Disease